EXPRESSION AND SIGNIFICANCE OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR γ IN KELOID_Chinese Journal of Reparative and Reconstructive Surgery

Authors：

LEILei ¹ , DENGYiling ² ,  CHENJunjie ¹ ,  CENYing ¹

1. Department of Burn and Plastic Surgery, West China Hospital, Sichuan University, 610041, P. R. China;
2. School of Basic Medical Sciences, Sichuan University;

Corresponding author：

CHENJunjie, Email: cjjemail@163.com; CENYing, Email: cenying0141@163.com

Keywords：

Keloid; Peroxisome proliferator activated receptor γ; Immunohistochemistry

DOI：

10.7507/1002-1892.20160233

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the expression and significance of peroxisome proliferator activated receptor γ(PPAR-γ) in human keloid. Methods Twenty-three keloid samples were harvested from the patients undergoing keloid and auto-skin grafting operation as the experimental group (keloid group), and the residual normal skin after auto-skin grafting operation was collected as the control group. The expression of PPAR-γ protein was examined by immunohistochemistry staining in both keloid and normal skin. Referring to Shimizu immunohistochemical standard, the result was graded; the positive rate of samples and the rate of positive cells were calculated. Results Immunohistochemistry staining showed that PPAR-γ protein was expressed in both keloid and normal skin. In keloid, it located in the pricle cell layer, and granular layer of epidermis, and the dermal vessel; the degree of dyeing was very light. However, in normal skin, it located in the base layer of epidermis, dermal vessel walls, sweat glands and sebaceous glands; the dyeing degree was deeper. Immunohistochemical staining score in the keloid group (2.65±0.78) was significantly lower than that in the control group (3.65±1.19) (t=5.030, P=0.000). The positive rate of samples in the keloid group (52.17%, 12/23) was significantly lower than that in the control group (82.61%, 19/23) (χ²=4.847, P=0.028). The rate of positive cells was 46.04%±8.61% in the keloid group, which was significantly lower than that in the control group (59.39%±11.26%) (t=5.974, P=0.000). Conclusion Compared with normal skin, the expression of PPAR-γ protein in keloid is down-regulated in in human keloid, indicating that PPAR-γ may be related to the formation of keloid.

Citation： LEILei, DENGYiling, CHENJunjie, CENYing. EXPRESSION AND SIGNIFICANCE OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR γ IN KELOID. Chinese Journal of Reparative and Reconstructive Surgery, 2016, 30(9): 1143-1145. doi: 10.7507/1002-1892.20160233 Copy

1.	Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature, 2000, 405(6785):421-424.
2.	Reddy RC. Immunomodulatory role of PPAR-gama in alveolarm acrophages. J Investig Med, 2008, 56(2):522-527.
3.	Shimizu M, Saitoh Y, Itoh H. Immunohistochemical staining of Ha-ras oncogene product in normal, benign, and malignant human pancreatic tissues. Hum Pathol, 1990, 21(6):607-612.
4.	Zhang GY, Cheng T, Zheng MH, et al. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist inhibits transforming growth factor-betal and matrix production in human dermal fibroblasts. J Plast Reconstr Aesthet Surg, 2010, 63(7):1209-1216.
5.	Wu M, Melichian DS, Chang E, et al. Rosiglitazong abrogates bleomycin-induced scleroderma and blocks profibrotic responses through PPAR-γ. Am J Pathol, 2009, 174(2):519-533.
6.	Pascul G, Sullivan AL, Ogawa S, et al. Anti-inflammatory and antidiabetic roles of PPAR-gamma. Novartis Found Symp, 2007, 286:183-203.
7.	潘晓娟, 张光峰, 董光富, 等.过氧化物酶体增殖物激活受体γ在结缔组织病相关的肺间质病变中抗纤维化作用机制研究.中华风湿病学杂志, 2013, 17(4):231-235.
8.	刘强, 王超云, 马小松, 等.过氧化物酶体增殖物激活受体γ(PPAR-γ)与肝纤维化的研究进展.滨州医学院学报, 2013, 36(1):49-51.
9.	Wang Z, Xu JP, Zheng YC, et al. Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats. Hepatob Pancreat Dis Int, 2011, 10(1):64-71.
10.	康谊, 曾艳丽, 魏君锋, 等. PPARγ在大鼠肝纤维化形成过程中的动态变化.基础医学与临床, 2013, 33(10):1324-1325.
11.	黄津, 张一. LX-2细胞中PPARγ对iNOS的影响及其抗肝纤维化作用.中国肝脏病杂志(电子版), 2015, 7(2):59-64.
12.	Miyahara T, Schrum L, Rippe R, et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem, 2000, 275(46):35715-35722.
13.	Guo YT, Leng XS, Li T, et al. Effect of ligand of peroxisome proliferator-activated receptor gamma on biological characters of hepatic stellate cells. World J Gastroenterol, 2005, 11(30):4735-4739.
14.	金国萍, 应利君, 童海明, 等.核受体PPARγ在醛固酮诱导大鼠急性肾损伤中的作用研究.浙江医学, 2015, 37(14):1196-1198, 1208.
15.	李相友, 丁国华, 夏瑗瑜, 等.血管紧张素1-7对糖尿病大鼠肾小管间质纤维化的影响.中华肾脏病杂志, 2012, 28(10):798-803.
16.	孙鹏.不同剂量PPARγ激动剂对非糖尿病肥胖小鼠血清脂联素、尿蛋白排泄及肾脏病理改变的相关性研究.天津:天津医科大学, 2014.
17.	侯定善, 张晓梅.过氧化物酶体增生物激活受体γ及其激动剂在眼科疾病中的作用.中华实验眼科杂志, 2014, 32(10):954-960.
18.	赵树梅, 李虹伟, 沈潞华.过氧化物酶体增殖物激活受体γ通路激活对糖尿病大鼠心肌纤维化的影响.中华老年多器官疾病杂志, 2010, 9(6):525-528.
19.	聂树涛. PPARγ激动剂对增生性瘢痕成纤维细胞TGF-β₁和Smad信号途径的作用研究.中国美容医学, 2011, 20(7):1098-1099.
20.	张义鹏, 解学关, 高伟阳, 等. PPAR-γ在增生性瘢痕中的表达及意义.医学研究杂志, 2012, 41(4):145-148.

1. Kersten S, Desvergne B, Wahli W. Roles of PPARs in health and disease. Nature, 2000, 405(6785):421-424.
2. Reddy RC. Immunomodulatory role of PPAR-gama in alveolarm acrophages. J Investig Med, 2008, 56(2):522-527.
3. Shimizu M, Saitoh Y, Itoh H. Immunohistochemical staining of Ha-ras oncogene product in normal, benign, and malignant human pancreatic tissues. Hum Pathol, 1990, 21(6):607-612.
4. Zhang GY, Cheng T, Zheng MH, et al. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist inhibits transforming growth factor-betal and matrix production in human dermal fibroblasts. J Plast Reconstr Aesthet Surg, 2010, 63(7):1209-1216.
5. Wu M, Melichian DS, Chang E, et al. Rosiglitazong abrogates bleomycin-induced scleroderma and blocks profibrotic responses through PPAR-γ. Am J Pathol, 2009, 174(2):519-533.
6. Pascul G, Sullivan AL, Ogawa S, et al. Anti-inflammatory and antidiabetic roles of PPAR-gamma. Novartis Found Symp, 2007, 286:183-203.
7. 潘晓娟, 张光峰, 董光富, 等.过氧化物酶体增殖物激活受体γ在结缔组织病相关的肺间质病变中抗纤维化作用机制研究.中华风湿病学杂志, 2013, 17(4):231-235.
8. 刘强, 王超云, 马小松, 等.过氧化物酶体增殖物激活受体γ(PPAR-γ)与肝纤维化的研究进展.滨州医学院学报, 2013, 36(1):49-51.
9. Wang Z, Xu JP, Zheng YC, et al. Peroxisome proliferator-activated receptor gamma inhibits hepatic fibrosis in rats. Hepatob Pancreat Dis Int, 2011, 10(1):64-71.
10. 康谊, 曾艳丽, 魏君锋, 等. PPARγ在大鼠肝纤维化形成过程中的动态变化.基础医学与临床, 2013, 33(10):1324-1325.
11. 黄津, 张一. LX-2细胞中PPARγ对iNOS的影响及其抗肝纤维化作用.中国肝脏病杂志(电子版), 2015, 7(2):59-64.
12. Miyahara T, Schrum L, Rippe R, et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem, 2000, 275(46):35715-35722.
13. Guo YT, Leng XS, Li T, et al. Effect of ligand of peroxisome proliferator-activated receptor gamma on biological characters of hepatic stellate cells. World J Gastroenterol, 2005, 11(30):4735-4739.
14. 金国萍, 应利君, 童海明, 等.核受体PPARγ在醛固酮诱导大鼠急性肾损伤中的作用研究.浙江医学, 2015, 37(14):1196-1198, 1208.
15. 李相友, 丁国华, 夏瑗瑜, 等.血管紧张素1-7对糖尿病大鼠肾小管间质纤维化的影响.中华肾脏病杂志, 2012, 28(10):798-803.
16. 孙鹏.不同剂量PPARγ激动剂对非糖尿病肥胖小鼠血清脂联素、尿蛋白排泄及肾脏病理改变的相关性研究.天津:天津医科大学, 2014.
17. 侯定善, 张晓梅.过氧化物酶体增生物激活受体γ及其激动剂在眼科疾病中的作用.中华实验眼科杂志, 2014, 32(10):954-960.
18. 赵树梅, 李虹伟, 沈潞华.过氧化物酶体增殖物激活受体γ通路激活对糖尿病大鼠心肌纤维化的影响.中华老年多器官疾病杂志, 2010, 9(6):525-528.
19. 聂树涛. PPARγ激动剂对增生性瘢痕成纤维细胞TGF-β₁和Smad信号途径的作用研究.中国美容医学, 2011, 20(7):1098-1099.
20. 张义鹏, 解学关, 高伟阳, 等. PPAR-γ在增生性瘢痕中的表达及意义.医学研究杂志, 2012, 41(4):145-148.

Chinese Journal of Reparative and Reconstructive Surgery

EXPRESSION AND SIGNIFICANCE OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR γ IN KELOID

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content